Literature DB >> 1982652

Central and peripheral hypotensive activity of urapidil and its M1 and M2 metabolites in the cat.

H Boss1, R Boer, K D Beller, K H Sanders.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982652     DOI: 10.2165/00003495-199000404-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  10 in total

1.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

2.  Selectivity of some alpha adrenoceptor agonists for peripheral alpha-1 and alpha-2 adrenoceptors in the normotensive rat.

Authors:  J C van Meel; A de Jonge; P B Timmermans; P A van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

Review 3.  Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+.

Authors:  K P Minneman
Journal:  Pharmacol Rev       Date:  1988-06       Impact factor: 25.468

4.  Differentiation of pre- and post-synaptic high affinity serotonin receptor binding sites using physico-chemical parameters and modifying agents.

Authors:  M D Hall; H Gozlan; M B Emerit; S el Mestikawy; L Pichat; M Hamon
Journal:  Neurochem Res       Date:  1986-06       Impact factor: 3.996

5.  Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists.

Authors:  G Hanft; G Gross
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

Review 6.  Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil.

Authors:  N Kolassa; K D Beller; K H Sanders
Journal:  Am J Cardiol       Date:  1989-08-15       Impact factor: 2.778

7.  Deviating central hypotensive activity of urapidil in the cat.

Authors:  P A van Zwieten; M J Mathy; M J Thoolen
Journal:  J Pharm Pharmacol       Date:  1985-11       Impact factor: 3.765

8.  Biotransformation of urapidil: metabolites in serum and urine and their biological activity in vitro and in vivo.

Authors:  K Zech; M Eltze; U Kilian; K H Sanders; N Kolassa
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-12

Review 9.  Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H D Langtry; G J Mammen; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

10.  Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors.

Authors:  A Pazos; D Hoyer; J M Palacios
Journal:  Eur J Pharmacol       Date:  1984-11-27       Impact factor: 4.432

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.